MetaCap

Heartbeam Inc. (BEAT)

NASDAQ: BEATHealth CareMedical/Dental InstrumentsUSD

0.2751-0.0338 (-10.94%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BEAT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$17.42M
EPS (TTM)
-$0.39
52-week range
0.2727 – 4.00
Day range
0.2727 – 0.314
Volume / Avg
658.30K / 7.50M
Beta
—

52-week range

$0.2727$4.00

BEAT stock today

On Nov 20, BEAT ended the session at $0.2751, shedding $0.0338 (10.94%), versus the S&P 500's 3.70% decline. Trading was light, with 658.30K shares changing hands, about 9% of the average daily volume. At this level, BEAT sits near the bottom of its 52-week range of $0.2727 to $4.00: 93.1% below the high, set on Dec 17, 2025 and 0.9% above the low.

BEAT is down 88.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 64.8%. Heartbeam has posted a net loss over the last twelve months (EPS of -$0.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Heartbeam

Company profile

HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician portal, and powerful cloud-based algorithms.

Industry
Medical/Dental Instruments
Headquarters
Santa Clara, CA
Employees
16
IPO year
2021

Financial highlights

Full financials

Heartbeam reported a net loss of $21.0 million, compared with a loss of $19.4 million a year earlier. Diluted earnings per share came in at -$0.62.

Heartbeam annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-21.02M$-19.45M$-14.64M$-12.96M$-4.43M
EPS (diluted)$-0.62$-0.73$-0.72$-1.59$-1.03

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$3.50+1172.26%

  • Strong buy 1
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.05 vs $-0.09
Surprise
+44.44%

BEAT news

All BEAT news

Heartbeam peers

Health Care sector
BEAT peer companies
CompanyPrice% ChgMarket capCompare
PMIPicard Medical Inc.6.79+7.78%$18.07Mvs BEAT
RVPRetractable Technologies Inc.0.558-6.84%$16.70Mvs BEAT
MODDModular Medical Inc.1.68-11.81%$16.36Mvs BEAT
DRIODarioHealth Corp.1.32-8.33%$14.90Mvs BEAT
CVRXCVRx Inc.0.501-5.99%$14.27Mvs BEAT
CTSOCytosorbents Corporation4.16-18.91%$13.12Mvs BEAT
SNWVSANUWAVE Health Inc.1.50-5.66%$12.90Mvs BEAT
DAVIDavion Healthcare Plc0.9001-9.99%$22.50Mvs BEAT

Indexes, lists and sector

Heartbeam stock FAQ

What is Heartbeam's stock price today?

BEAT last traded at $0.2751 as of Nov 20, 4:00 PM EST, down 10.94% on the day. Prices are delayed at least 15 minutes.

What is the BEAT 52-week high?

The 52-week high for BEAT is $4.00 and the 52-week low is $0.2727. The stock is currently 93.1% below its high.

Compare BEAT